Beta Bionics, Inc. (BBNX) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended September 2025, Beta Bionics, Inc. (BBNX) reported revenue of $27.25 million, representing no change compared to the same period last year. EPS came in at -$0.33, compared to $0 in the year-ago quarter.

The reported revenue represents a surprise of +13.96% over the Zacks Consensus Estimate of $23.92 million. With the consensus EPS estimate being -$0.45, the EPS surprise was +26.67%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Beta Bionics, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Total DME channel: $21.02 million compared to the $16.22 million average estimate based on two analysts.
• Revenues- Total PBP channel: $6.24 million compared to the $5.65 million average estimate based on two analysts.
• Revenues- PBP channel- Single-use products: $6.09 million compared to the $5.94 million average estimate based on two analysts.
• Revenues- DME channel- Single-use products: $6.84 million compared to the $5.48 million average estimate based on two analysts.
• Revenues- PBP channel- iLet: $0.15 million versus $0.5 million estimated by two analysts on average.
• Revenues- DME channel- iLet: $14.18 million compared to the $10.74 million average estimate based on two analysts.

View all Key Company Metrics for Beta Bionics, Inc. here>>>

Shares of Beta Bionics, Inc. have returned +19.6% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Beta Bionics, Inc. (BBNX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research